Skip to main content

Ionis Pharmaceuticals Inc (IONS) Stock

Ionis Pharmaceuticals Inc Stock Details, Movements and Public Alerts

Stock Details

Ionis Pharmaceuticals Inc (IONS), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $71.44. Over the past 52 weeks, it has ranged between $23.95 and $76.78. This places the current price at 93.0% of its 52-week high and 198.3% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 61.53, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $67.11 by 6.45%. Similarly, it is above its 200-day moving average of $43.28 by 65.06%. The MACD histogram is -0.40, indicating bearish momentum (MACD Line: 2.17, Signal Line: 2.57). There is currently 1 active alert set for IONS by users.

52-Week Range

$76.78 - $23.95

-6.95% from high · +198.29% from low

Avg Daily Volume

2,083,071

20-day average

100-day avg: 2,328,906

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

90.91

PEG Ratio

25.70

Potentially overvalued

Price to Book

17.26

EV/EBITDA

-22.08

EPS (TTM)

-$1.61

Price to Sales

12.32

Beta

0.31

Less volatile than market

How is IONS valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is IONS's risk profile compared to the market?
With a beta of 0.31, Ionis Pharmaceuticals Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 17.26 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-26.50%

Operating Margin

-102.20%

EBITDA

$-266,799,008

Return on Equity

-40.00%

Return on Assets

-5.68%

Revenue Growth (YoY)

17.10%

Earnings Growth (YoY)

-43.70%

How profitable and efficient is IONS's business model?
Ionis Pharmaceuticals Inc achieves a profit margin of -26.50%, meaning it retains $-26.50 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -102.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -40.00% and ROA at -5.68%, the company achieves moderate returns on invested capital.
What are IONS's recent growth trends?
Ionis Pharmaceuticals Inc's revenue grew by 17.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 43.70% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$11.9B

Revenue (TTM)

$966.96M

Revenue/Share (TTM)

$6.08

Shares Outstanding

161.97M

Book Value/Share

$3.84

Asset Type

Common Stock

What is IONS's market capitalization and position?
Ionis Pharmaceuticals Inc has a market capitalization of $11.9B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 161.97M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does IONS's price compare to its book value?
Ionis Pharmaceuticals Inc's book value per share is $3.84, while the current stock price is $71.44, resulting in a price-to-book (P/B) ratio of 18.63. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$82.43

15.38% upside potential

Analyst Recommendations

Strong Buy

8

Buy

10

Hold

7

Sell

0

Strong Sell

0

How reliable are analyst predictions for IONS?
25 analysts cover IONS with 72% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $82.43 implies 15.4% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on IONS?
Current analyst recommendations:8 Strong Buy, 10 Buy, 7 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 10, 2025, 08:25 AM

Technical Indicators

RSI (14-day)

61.53

Neutral

50-Day Moving Average

$67.11

6.45% above MA-50

200-Day Moving Average

$43.28

65.06% above MA-200

MACD Line

2.17

MACD Signal

2.57

MACD Histogram

-0.40

Bearish

What does IONS's RSI value tell investors?
The RSI (Relative Strength Index) for IONS is currently 61.53, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret IONS's MACD and moving average crossovers?
MACD analysis shows the MACD line at 2.17 below the signal line at 2.57, with histogram at -0.40. This bearish crossover indicates downward pressure. The 50-day MA ($67.11) is above the 200-day MA ($43.28), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Nov 10, 2025, 01:06 PM

Active Alerts

Alert Condition
Forward P/E falls below
Threshold
70 x
Created
Nov 10, 2025, 08:25 AM

Stay Ahead of the Market with Ionis Pharmaceuticals Inc Alerts

Set up price alerts for Ionis Pharmaceuticals Inc and get notified instantly when the price hits your target. Never miss an important price movement again.